Healthcare · NSE: DRREDDY · BSE: 500124
Dr. Reddy's: how the business works
Dr. Reddy's makes generic and branded medicines and their ingredients, and sells them in 87 countries; FY26 revenue was ₹33,700 crore.
Follow Dr. Reddy's
Email me when Dr. Reddy's's page is updated after results.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
Dr. Reddy's Laboratories Limited · Hyderabad, Telangana · Founded 1984
Updated for Q2 FY27 · checked
- Revenue, FY26
- ₹33,700 cr
- Profit to shareholders, FY26
- ₹4,196 cr
- Countries it sells in, FY26
- 87
- Permanent employees, FY26
- 27,527
- Promoter holding, Sep 2026 (none pledged)
- 26.63%
The short version
Dr. Reddy's in 5 points
1 · What it sells
The company makes generic and branded medicines and the active ingredients that go into them, and its FY26 revenue from operations was ₹33,700 crore.
2 · Who pays it
In FY26, customers in the US paid 35.1% of the company's revenue, customers in India 19.2%, Russia 10.4% and all other countries 35.3%.
3 · What it keeps from ₹100
Of every ₹100 that came in during FY26, including ₹1,358 crore of other income, the company kept ₹12.0 as profit for shareholders, and its operating EBITDA margin on revenue was 19.1% (Cityfort calculation, after ₹352 crore of write-downs).
4 · Where the operating profit comes from
Global Generics earned ₹16,970 crore of the company's ₹17,728 crore FY26 gross profit, while active ingredients and services (PSAI) earned ₹600 crore.
5 · The one thing to watch
US lenalidomide exclusivity ended in Jan 2026, and the company's North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier by its own count.
Sources: From Dr. Reddy's FY26 annual report, its Q4 FY26 and Q2 FY27 results filings and presentation, and ICRA's Jan 2026 rating report · checked
Sources (5)
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
- Integrated Annual Report FY2025-26
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Q2 FY27 results presentation (IFRS)
01Where the money goes · FY26
Where does ₹100 of Dr. Reddy's' money go?
Dr. Reddy's · FY26
Receipt for every ₹100
| Materials and goods bought | ₹34.9 |
|---|---|
| Employees | ₹17.1 |
| Other running costs (incl. write-downs) | ₹25.7 |
| Depreciation and amortisation | ₹5.9 |
| Interest | ₹1.1 |
| Income tax | ₹3.5 |
| Kept as profit for shareholders | ₹12.0 |
| Total | ₹100 |
Each line = amount ÷ total money in × 100. Lines may not add to exactly ₹100 because of rounding.
How this is worked out
Cityfort calculation from the FY26 audited results: each line ÷ ₹35,110 crore that came in (revenue ₹33,700 crore, other income ₹1,358 crore, and ₹52 crore from associates and minority partners' share of losses). Other running costs include ₹352 crore of write-downs. ₹12.0 was kept as profit; rounded lines add to 100.2.
Save this receipt as an image
Embed this receipt or the key numbers
Paste this code into a blog or website to show the card you choose, with a link back to this page.
Each week: the next company due to report results, explained in 5 points.
We'll email you once a week with what changed on Cityfort. Facts only, no tips. Unsubscribe any time.
We store your email address with Kit, our email provider, which also records when you sign up and whether you open or click our emails. We send a confirmation email first. See our privacy policy.
02The business in one line
What does Dr. Reddy's do?
Drug wholesalers, pharmacies, hospitals and other drug makers pay Dr. Reddy's for medicines and ingredients; materials take ₹34.9 of every ₹100, and ₹12.0 is profit.
- Customers in the US paid 35.1% of FY26 revenue, down from 45.9% in FY25, after US lenalidomide exclusivity ended in Jan 2026.
- Profit for shareholders fell 25.8% in FY26, to ₹4,196 crore, and fell 50.5% in H1 FY27 from a year earlier.
03Who pays it
Who pays Dr. Reddy's?
Buyers of finished medicines
88.9%
of revenue
Wholesalers, distributors, pharmacy chains, hospitals and government institutions buying the Global Generics segment's medicines. Share is of FY26 revenue.
Other drug makers
10.5%
of revenue
Buy active ingredients and contract research and manufacturing services (PSAI segment). Share is after removing PSAI's sales to Dr. Reddy's own generics business.
Others
0.6%
of revenue
Aurigene Oncology (a drug discovery business) and proprietary products.
- Buyers of finished medicines88.9%
- Other drug makers10.5%
- Others0.6%
How spread out the customers are
The Indian filings do not disclose revenue by customer. The FY26 BRSR lists customer types only.
04How it makes money
How does Dr. Reddy's make money?
Profit has followed US generics: it fell after US lenalidomide exclusivity ended in Jan 2026.
ICRA's Jan 2026 report lists price competition in US generics as a challenge. After US lenalidomide exclusivity ended in Jan 2026, North America revenue fell 22% in FY26 (company figures). Dr. Reddy's kept ₹19.9 of profit per ₹100 of revenue in FY24 and ₹12.5 in FY26.
Profit for shareholders per ₹100 of revenue
₹19.9₹12.5
FY24 to FY26
- Dr. Reddy's files to sell copies of medicines whose patents are ending (77 US applications pending, Sep 2026).
- Its own ingredient plants supply many of the active ingredients.
- An early approval can mean few rival sellers for a while.
- Rivals arrive and prices fall, as with lenalidomide after Jan 2026.
- Profits pay for R&D, 7.2% of FY26 revenue by the company's count, and the next filings.
- Branded businesses (India, emerging markets and nicotine gums) were 53% of Q2 FY27 revenue (company figure).
↺ Step 6 feeds back into step 1.
Sources (5)
- Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Q2 FY27 results presentation (IFRS)
05Business segments · FY26
Which businesses make up Dr. Reddy's?
Global Generics
88.9%Finished medicines in North America, Europe, India and emerging markets, including biosimilars and nicotine gums. FY26 gross profit was ₹16,970 crore of the company's ₹17,728 crore.
Revenue ₹29,946 cr
Pharmaceutical Services and Active Ingredients (PSAI)
10.5%Active ingredients and contract services for other drug makers, shown after ₹727 crore of sales to Global Generics. FY26 gross profit was ₹600 crore.
Revenue ₹3,540 cr
Others
0.6%Aurigene Oncology (drug discovery) and proprietary products. FY26 gross profit was ₹158 crore.
Revenue ₹214 cr
How the mix changed
- Global Generics
- Pharmaceutical Services and Active Ingredients (PSAI)
- Others
Revenue by segment, FY25 to FY26.
₹ crore
See the numbers
06The numbers · Consolidated · ₹ crore
How has Dr. Reddy's done?
Revenue
₹33,700 crFY26
Revenue rose every year from ₹21,545 crore in FY22 to ₹33,700 crore in FY26; Q2 FY27 revenue of ₹8,698 crore was 1.5% below Q2 FY26.
₹ crore
See the numbers
Net profit
₹4,196 crFY26
Q4 FY26 profit of ₹221 crore carried a ₹453 crore lenalidomide shelf-stock adjustment and write-downs, and Q1 FY27 (₹444 crore) a ₹239.7 crore semaglutide provision.
₹ crore
See the numbers
Net profit for every ₹100 of revenue
₹12.5FY26
Dr. Reddy's kept ₹10.1 of profit per ₹100 of revenue in FY22, ₹19.9 in FY24 and ₹12.5 in FY26; FY26 EBITDA margin was 19.1% by Cityfort's calculation and 22.8% by the company's own IFRS figure.
Net margin: ₹ of net profit per ₹100 of revenue
See the numbers
Free cash flow
₹1,833 crFY26
Free cash flow was ₹1,833 crore in FY26 and −₹367 crore in H1 FY27, when a USD 50 million lenalidomide claim was paid, the CFO said.
₹ crore · cash from operations minus spending on plants and equipment
See the numbers
See all yearly numbers
EBITDA = profit before interest, tax and wear-and-tear of assets. Financial year runs April to March (March year end). Net profit is the share belonging to the company's owners. Total net income differs from net profit to the company's owners: Minority partners bore ₹38 crore of losses, so profit for Dr. Reddy's shareholders is above total profit.
Sources (17)
- Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY24 results filing (PDF; FY23 comparatives)
- Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS)
- Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL)
- Integrated Annual Report FY2025-26
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Q3 FY25 consolidated financial results (Ind AS, NSE XBRL)
- Q1 FY26 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY26 consolidated financial results (Ind AS, NSE XBRL)
- Q3 FY26 consolidated financial results (Ind AS, NSE XBRL)
- Q1 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q1 FY27 results filing (PDF, notes)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY27 results filing: board outcome and financial results (PDF)
07Who runs it
Who runs Dr. Reddy's, and did they deliver?
K Satish Reddy
Chairman & Whole-time Director · since 2014
Part of the promoter group. Managing Director from 1997 and Chairman from 13 May 2014.
G V Prasad
Co-Chairman & Managing Director
Part of the promoter group. Re-appointed for five years from 30 Jan 2026.
Erez Israeli
Chief Executive Officer
M V Narasimham
Chief Financial Officer
Akhil Ravi
Head, API and Services · since 2026
Appointed from 13 Nov 2026, after Deepak Sapra resigned as CEO of API and Services.
K Randhir Singh
Company Secretary
What they said, and what happened
1 delivered · 1 withdrawn · 4 too early to tell
Said on 23 Jul 2025
Appoint Deloitte Haskins & Sells LLP as statutory auditors from FY27, in a mandatory rotation.
DeliveredWhat happened
Shareholders appointed Deloitte at the AGM on 23 Jul 2026, for five years.
Said on 12 May 2026
Sell about 10 to 11 million semaglutide pens in FY27, near the 12 million discussed earlier (management, Q4 FY26 call).
WithdrawnWhat happened
On 9 Jul 2026 the company said batches failed specification because of an ingredient issue. On 22 Jul 2026 management spoke of 6 to 7 million pens between November and March.
Said on 12 May 2026
Gross margin to improve and be above 50% in FY27 (management, Q4 FY26 call).
Too early to tellWhat happened
The company's own gross margin figure (IFRS) was 46.5% in Q1 FY27 and 52.1% in Q2 FY27.
Said on 12 May 2026
Keep the EBITDA margin of the business without semaglutide at around 20% (management, Q4 FY26 call; a company IFRS measure).
Too early to tellWhat happened
The company's EBITDA margin was 12.5% in Q1 FY27 (15.4% without semaglutide) and 20.6% in Q2 FY27.
Said on 12 May 2026
Effective tax rate of 24 to 25% for FY27 (management, Q4 FY26 call).
Too early to tellWhat happened
In H1 FY27 tax was 24.2% of profit before tax (Cityfort calculation from the Q1 and Q2 FY27 results).
Said on 22 Jul 2026
Resume semaglutide commercial supplies by November 2026 (management, Q1 FY27 call).
Too early to tellWhat happened
On 23 Oct 2026 management said it expected to re-launch in November 2026, subject to successful validation.
Sources (13)
- Integrated Annual Report FY2025-26
- AGM 24 Jul 2025 outcome: re-appointment of G V Prasad as Co-Chairman and MD
- Intimation: appointment of Akhil Ravi as Head API and Services
- Intimation: resignation of Deepak Sapra, CEO API and Services
- Press release: intention to appoint Deloitte Haskins & Sells LLP as statutory auditors from FY2026-27
- AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments
- Q4 FY26 earnings call transcript (12 May 2026)
- Intimation: semaglutide batches out of specification due to API issue; supplies delayed
- Q1 FY27 earnings call transcript (22 Jul 2026)
- Q2 FY27 results presentation (IFRS)
- Q1 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY27 earnings call transcript (23 Oct 2026)
08What could go wrong
What could go wrong for Dr. Reddy's?
- Competition
Price competition in US generics
US customers paid 35.1% of FY26 revenue, down from 45.9% in FY25. After lenalidomide exclusivity ended in Jan 2026, North America revenue fell 23% in Q2 FY27 (company figure). ICRA lists US generics price competition as a challenge.
Watch North America revenue each quarter (₹2,489 crore in Q2 FY27, company figure).
- Regulation
US FDA inspection findings
Plants that supply the US must pass US FDA inspections. As of 11 Nov 2026 the company had disclosed four inspections with Form 483s and one records assessment (Form FDA 2953) with no final classification, including 7 observations at its biologics plant in Jun 2026.
Watch FDA classification of the open inspections, and any warning letter or import alert.
- Execution
Semaglutide supply problem
On 9 Jul 2026 the company said semaglutide batches failed specification because of an ingredient (API) issue. Q1 FY27 carried a ₹239.7 crore provision for inventory and related costs.
Watch Whether semaglutide supplies resume, and semaglutide sales in Q3 and Q4 FY27.
- Legal
Pending US antitrust lawsuits
US class actions allege price-fixing of generic medicines, and other suits make antitrust claims over Revlimid (lenalidomide). The company says most amounts cannot be reasonably estimated and has made no provision.
Watch Court rulings, and any provision in the results notes.
- Regulation
Russia taxes and exposure
Customers in Russia paid 10.4% of FY26 revenue. FY26 included Russian VAT provisions of ₹69.5 crore in Q2 and ₹114.1 crore in Q4.
Watch Russia revenue (₹1,008 crore in Q2 FY27, company figure) and any new tax provisions.
- Cash and liquidity
Weaker cash flow in H1 FY27
Operating cash flow was ₹435 crore in H1 FY27, against ₹3,020 crore in H1 FY26. After ₹802 crore of capex, free cash flow was −₹367 crore.
Watch Operating cash flow in the H2 FY27 results.
- Execution
Write-downs on research bets
FY26 included ₹352 crore of write-downs, among them ₹129.1 crore for a stopped CAR-T programme and ₹91.4 crore for eftilagimod alfa, whose Phase III trial was stopped for futility.
Watch Impairment charges in each quarter's results.
Sources (16)
- Integrated Annual Report FY2025-26
- Q2 FY27 results presentation (IFRS)
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations
- Intimation: US FDA GMP inspection at formulations facility FTO-3, Bachupally: Form 483 with 4 observations
- Intimation: US FDA records assessment at API facility, Mexico: Form FDA 2953 with 2 observations
- Intimation: US FDA PAI at FTO-11, Pydibhimavaram: Form 483 with 2 observations
- Intimation: US FDA PAI at FTO-9, Visakhapatnam: Form 483 with 3 observations
- Intimation: semaglutide batches out of specification due to API issue; supplies delayed
- Q1 FY27 results filing (PDF, notes)
- Q2 FY27 earnings call transcript (23 Oct 2026)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY26 consolidated financial results (Ind AS, NSE XBRL)
- Disclosure: Immutep update on TACTI-004 Phase III (eftilagimod alfa)
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
09Supporters and critics
What do supporters and critics point to?
What supporters point to
- Revenue rose every year, from ₹21,545 crore in FY22 to ₹33,700 crore in FY26.
- In Q2 FY27 emerging markets revenue rose 24% and India 17% from a year earlier (company figures).
- On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore; ICRA rates the company AA+/Stable.
- No promoter shares were pledged in any of the 12 quarters to Sep 2026.
- The company says North America revenue excluding lenalidomide rose 29% in Q2 FY27.
What critics point to
- Profit for shareholders fell 25.8% in FY26, and 50.5% in H1 FY27 from a year earlier.
- US customers' share of revenue fell from 45.9% in FY25 to 35.1% in FY26.
- From Jun to Oct 2026, four FDA inspections with Form 483s and one records assessment (Form FDA 2953) ended with observations, not yet classified as of 11 Nov 2026.
- Semaglutide supplies stopped after batches failed specification; Q1 FY27 carried a ₹239.7 crore provision.
- Free cash flow was −₹367 crore in H1 FY27.
10What to watch next
What should you watch next at Dr. Reddy's?
Next event
Q3 FY27 results
Date not announced yet.
Semaglutide re-launch
Management said on the Q2 FY27 call (23 Oct 2026) it expected to re-launch semaglutide in November 2026, subject to validation; on 22 Jul 2026 it spoke of 6 to 7 million pens between November and March.
US FDA outcomes
The biologics plant got 7 observations in a Jun 2026 pre-licence inspection, and the abatacept biosimilar awaits US approval.
North America after lenalidomide
North America revenue was ₹2,489 crore in Q2 FY27, 23% lower than a year earlier (company figure). Q3 FY26 results were filed on 21 Jan 2026.
11Key facts
Key facts about Dr. Reddy's
- What does Dr. Reddy's do?
- Dr. Reddy's Laboratories, based in Hyderabad, makes generic and branded medicines and their active ingredients. Dr. Reddy's sold in 87 countries in FY26, and its FY26 revenue from operations was ₹33,700 crore.
- How does Dr. Reddy's make money?
- Dr. Reddy's earns most of its money from finished medicines. Its Global Generics segment was 88.9% of FY26 revenue and earned ₹16,970 crore of Dr. Reddy's ₹17,728 crore gross profit. Active ingredients and services (PSAI) were 10.5% of revenue.
- Who are Dr. Reddy's customers?
- Dr. Reddy's sells to wholesalers, distributors, pharmacy chains, hospitals, government institutions and other drug makers. In FY26, customers in the US paid 35.1% of Dr. Reddy's revenue, India 19.2% and Russia 10.4%. Dr. Reddy's Indian filings do not disclose revenue by customer.
- How big is Dr. Reddy's?
- In FY26 Dr. Reddy's consolidated revenue from operations was ₹33,700 crore and its profit for shareholders was ₹4,196 crore. Dr. Reddy's had 27,527 permanent employees and 24 manufacturing facilities in FY26.
- Who owns Dr. Reddy's?
- On 30 Sep 2026 the promoter group, the families of K Satish Reddy and G V Prasad, held 26.63% of Dr. Reddy's, with no shares pledged. JP Morgan Chase Bank, depository for Dr. Reddy's US-listed ADRs, held 11.10% for ADR holders. Other foreign investors held 20.30%, Indian institutions 31.88% (LIC 12.14%) and individuals and others 9.90%.
- Why was Dr. Reddy's FY26 profit lower than FY25?
- Dr. Reddy's FY26 profit for shareholders of ₹4,196 crore was 25.8% below FY25's ₹5,655 crore. US lenalidomide exclusivity ended in Jan 2026, and Q4 FY26 revenue carried a ₹453 crore lenalidomide shelf-stock adjustment. FY26 also included ₹352 crore of write-downs (impairments).
- Does Dr. Reddy's have debt?
- On 30 Sep 2026 Dr. Reddy's had ₹5,826 crore of borrowings and ₹6,874 crore of cash, bank balances and short-term investments. ICRA rated Dr. Reddy's AA+ with a stable outlook on 9 Jan 2026.
- What dividend did Dr. Reddy's pay for FY26?
- Dr. Reddy's board recommended a final dividend of ₹8 per share for FY26 on 12 May 2026. That was 15.9% of Dr. Reddy's FY26 basic earnings per share of ₹50.41 (Cityfort calculation).
- Where are Dr. Reddy's shares listed?
- Dr. Reddy's shares trade on the NSE as DRREDDY and on the BSE as 500124. Dr. Reddy's American depositary receipts (ADRs) trade on the New York Stock Exchange as RDY.
Sources (8)
- Integrated Annual Report FY2025-26
- Business Responsibility and Sustainability Report FY2025-26
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
- Shareholding pattern as of Sep 2026 (NSE XBRL)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY27 results filing: board outcome and financial results (PDF)
Terms on this page
- Capital expenditure (capex)
- Credit rating
- Dividend payout ratio
- EBITDA
- FII and DII holding
- Free cash flow
- Market capitalisation
- Net debt
- Net profit
- Operating margin
Each explains the term in plain English, with the same number from other companies on Cityfort.
Go deeper
More detail from the same filings. Open any section.
12What it sells
12What it sells
What does Dr. Reddy's sell?
Generic medicines for North America
Copies of off-patent medicines sold in the US and Canada. The company's figure (IFRS) for FY26 was ₹11,374 crore, down 22% from FY25.
Branded medicines in India
Medicines sold in India under Dr. Reddy's brand names, including Obeda semaglutide from Mar 2026. The company's figure for FY26 was ₹6,219 crore, up 16%.
Emerging markets
Medicines sold in Russia, other CIS countries and the rest of the world. The company's figure for FY26 was ₹6,761 crore, up 23%.
Europe, including nicotine gums
Generics in Germany, the UK and other countries, plus nicotine replacement brands such as Nicotinell bought from Haleon. The company's figure for FY26 was ₹5,550 crore, up 55%.
Active ingredients and services (PSAI)
Active pharmaceutical ingredients (APIs, the chemicals that make a medicine work) and contract services for other drug makers. The company's figure for FY26 was ₹3,477 crore.
Biosimilars and partner products
Biosimilars are near-copies of medicines made from living cells. An abatacept biosimilar awaits US approval. On 18 Sep 2026 Dr. Reddy's signed an agreement to distribute Takeda's dengue vaccine Qdenga in India's private market, with launch planned for H1 2027.
Think of it like this
A generic medicine is like a copy of a book whose copyright has ended: any approved printer may print it.
What it does
- Does: Makes generic copies of off-patent medicines for the US, Europe, Russia and other markets
- Does: Sells branded medicines in India
- Does: Makes active ingredients for its own medicines and for other drug makers
- Does: Develops biosimilars, and signed an agreement (18 Sep 2026) to distribute Takeda's Qdenga vaccine in India's private market from H1 2027
What it does not do
- Does not: Report in only one set of accounts: it files Ind AS results (used on this page) and IFRS results
- Does not: Have any promoter shares pledged: none in the 12 quarters to Sep 2026
- Does not: Disclose revenue by customer in its Indian filings
- Does not: Sell Novartis India brands any more: that distribution deal ended, with sales until 30 Sep 2026
Sources (7)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Press release: launch of semaglutide injection (Obeda) in India
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Q2 FY27 results presentation (IFRS)
- Integrated Annual Report FY2025-26
- Q2 FY27 earnings call transcript (23 Oct 2026)
- Disclosure: exclusive distribution agreement with Takeda for Qdenga (India private market)
13How the money flows
13How the money flows · FY26
How does money flow through Dr. Reddy's?
Money in
- Revenue from operations₹33,700 cr
- Share of associates' profit and of losses borne by minority partners₹52 cr
- Other income₹1,358 cr
The company
Dr. Reddy's
₹35,110 cr came in
Money out
- Materials and goods bought₹12,239 cr
- Employee costs₹5,991 cr
- Other running costs (incl. ₹352 crore of write-downs)₹9,017 cr
- Depreciation and amortisation₹2,059 cr
- Interest₹374 cr
- Income tax₹1,235 cr
- Net profit for Dr. Reddy's shareholders₹4,196 cr
- In FY26 Dr. Reddy's sold ₹33,700 crore of medicines, ingredients and services, and had ₹1,358 crore of other income.
- Materials and goods bought took ₹12,239 crore, and employees ₹5,991 crore.
- Other running costs took ₹9,017 crore, including ₹352 crore of write-downs (impairments).
- Depreciation took ₹2,059 crore, interest ₹374 crore and income tax ₹1,235 crore.
- What was left for Dr. Reddy's shareholders was ₹4,196 crore of profit.
14What it needs to run
14What it needs to run
What does Dr. Reddy's need to run?
Factories
24 manufacturing facilities in FY26, according to the annual report. Plants that supply the US must pass US FDA inspections.
US product applications
77 generic applications (ANDAs) and 3 new-drug applications were pending with the US FDA in Sep 2026, including 47 patent challenges (Para IV) and 27 first-to-file.
Research
The company says R&D spending was 7.2% of FY26 revenue, down 12%, after most of its abatacept biosimilar investment was completed.
Own ingredient plants
The PSAI segment sold ₹727 crore of ingredients to Dr. Reddy's own generics business in FY26. ICRA says this backward integration gives a cost advantage.
People
27,527 permanent employees and 9,199 other workers in FY26, according to the BRSR.
Sources (5)
15Where it sells
15Where it sells · FY26
Where does Dr. Reddy's sell?
- United States35.1%
- India19.2%
- Russia10.4%
- Other countries35.3%
Sources (1)
16Competitors and what protects it
16Competitors and what protects it
Who does Dr. Reddy's compete with?
Sun Pharmaceutical Industries
NSE: SUNPHARMA
Ranked first in India's medicine market: ₹21,538 crore of India sales, an 8.5% share, in the 12 months to Jun 2026 (AIOCD data in its own presentation).
What protects the business
Each strength is scored 1 (weak) to 5 (strong) for the business, with the reason. It is not a rating of the share.
- Own ingredient supply4 of 5
The PSAI segment makes active ingredients and sold ₹727 crore of them to Dr. Reddy's own generics business in FY26. ICRA (Jan 2026) says this backward integration gives a significant cost advantage.
- Spread across markets4 of 5
In FY26 customers in the US paid 35.1% of revenue, India 19.2%, Russia 10.4% and other countries 35.3%. It sold in 87 countries.
- US filings pipeline3 of 5
77 generic and 3 new-drug applications were pending with the US FDA in Sep 2026, including 27 first-to-file.
- India brands3 of 5
The company says, citing IQVIA, it ranked 8th in India in the quarter to Sep 2026, and its India sales grew 21.0% against the market's 14.7%.
- Cash and borrowings4 of 5
On 30 Sep 2026 cash and short-term investments exceeded borrowings by ₹1,048 crore (Cityfort calculation). ICRA rated it AA+/Stable on 9 Jan 2026.
Weak spot
Reliance on US generics
US customers' share of revenue fell from 45.9% in FY25 to 35.1% in FY26 after lenalidomide exclusivity ended in Jan 2026. North America revenue fell 23% in Q2 FY27 (company figure).
Sources (6)
- Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026)
- Integrated Annual Report FY2025-26
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Business Responsibility and Sustainability Report FY2025-26
- Q2 FY27 results presentation (IFRS)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
17Where growth could come from
17Where growth could come from
Where could Dr. Reddy's' growth come from?
Management said on the Q2 FY27 call (23 Oct 2026) that it expected to re-launch semaglutide in November 2026, "subject to successful validation". CFO M V Narasimham said the company wants gross margin of 50 to 55% (a company IFRS measure).
Semaglutide (diabetes and weight-loss injection)
Behind₹239.7 crore provision, Q1 FY27
Launched in India in Mar 2026 and Canada in May 2026. On 9 Jul 2026 the company said batches failed specification because of an ingredient issue. It said on 5 Nov 2026 that Brazil had granted marketing authorisation.
Status: Behind, behind the company's own plan.
India
Working+17% YoY, Q2 FY27 (company figure)
India revenue was ₹1,851 crore in Q2 FY27. Citing IQVIA, the company says its India sales grew 21.0% against the market's 14.7%.
Status: Working, on track against what the company said.
Emerging markets
Working+24% YoY, Q2 FY27 (company figure)
Emerging markets revenue was ₹2,059 crore in Q2 FY27, including ₹1,008 crore from Russia. In FY26 it rose 23%.
Status: Working, on track against what the company said.
North America without lenalidomide
Mixed₹2,489 crore, −23% YoY, Q2 FY27
North America revenue fell 23% in Q2 FY27. The company says it rose 29% excluding lenalidomide.
Status: Mixed, partly on track.
Europe and nicotine gums
Mixed+1% YoY, Q2 FY27 (company figure)
Europe revenue rose 55% in FY26; the nicotine replacement business bought from Haleon is included from Q3 FY25. In Q2 FY27 Europe revenue was ₹1,393 crore, up 1%.
Status: Mixed, partly on track.
Abatacept biosimilar
EarlyUS approval awaited
Management said on 23 Oct 2026 that abatacept sales should reach hundreds of millions of dollars. The biologics plant got 7 observations in a Jun 2026 FDA pre-licence inspection.
Status: Early, too early to judge.
Status compares progress with what the company itself said it would do: Working = on track against what the company said; Mixed = partly on track; Behind = behind the company's own plan; New = recently announced; Early = too early to judge.
Sources (10)
- Q2 FY27 earnings call transcript (23 Oct 2026)
- Press release: launch of semaglutide injection (Obeda) in India
- Press release: launch of generic semaglutide injection in Canada
- Intimation: semaglutide batches out of specification due to API issue; supplies delayed
- Q1 FY27 results filing (PDF, notes)
- Press release: marketing authorization for generic semaglutide injection in Brazil
- Q2 FY27 results presentation (IFRS)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations
18Financial strength and debt
18Financial strength · 30 Sep 2026
How much debt does Dr. Reddy's have?
- Total debt₹5,826 cr
- Cash and investments₹6,874 cr
- Net cash (cash minus debt)₹1,048 cr
- Net worth (shareholders' money)₹38,807 cr
- Debt to equity
- 0.15×
- ₹ of debt for every ₹1 of shareholders' money
- Interest cover
- 8.1×
- how many times operating profit covers interest
- Cash and short-term investments = cash, other bank balances and current investments. All borrowings were short-term.
- Lease liabilities (rent owed under leases) were a further ₹1,403 crore; counting them, debt exceeded cash by ₹355 crore (Cityfort calculation).
- The company reports a "net cash surplus" of ₹2,502 crore on its own IFRS definition, which adjusts for non-current cash and borrowings.
- Borrowings rose from ₹1,652 crore on 31 Mar 2024 to ₹4,185 crore a year later, the year it bought the nicotine replacement business from Haleon.
- Interest cover = (profit before tax + interest) ÷ interest, H1 FY27 (Cityfort calculation). Debt to equity = borrowings ÷ total equity.
Sources (6)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY27 results presentation (IFRS)
- Q2 FY27 earnings call transcript (23 Oct 2026)
- Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL)
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
19Who owns it
19Who owns it · Q2 FY27
Who owns Dr. Reddy's?
- Promoters (founders or parent company)26.6%
- Foreign institutions (FII)20.3%
- Indian institutions (DII)31.9%
- Public and others21.0%
Promoter pledge
No promoter shares were pledged in Q2 FY27.
How ownership changed
* Pledged = share of the promoters' own holding reported as pledged. In older filings this can include shares “otherwise encumbered”; the governance flags say when.
† Others = Shares behind US-listed ADRs (held by JP Morgan Chase Bank as depository; filed inside foreign institutions).
Sources (13)
- Shareholding pattern as of Dec 2023 (NSE XBRL)
- Shareholding pattern as of Mar 2024 (NSE XBRL)
- Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL)
- Shareholding pattern as of Sep 2024 (NSE XBRL)
- Shareholding pattern as of Dec 2024 (NSE XBRL)
- Shareholding pattern as of Mar 2025 (NSE XBRL)
- Shareholding pattern as of Jun 2025 (NSE XBRL)
- Shareholding pattern as of Sep 2025 (NSE XBRL)
- Shareholding pattern as of Dec 2025 (NSE XBRL)
- Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL)
- Shareholding pattern as of Jun 2026 (NSE XBRL)
- Shareholding pattern as of Sep 2026 (NSE XBRL)
- Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust
20What it does with profit
20What it does with profit
What does Dr. Reddy's do with its profit?
Dividend per share
₹8.00FY26
Dividend paid for each share, by financial year.
₹ per share
See the numbers
No buybacks or fund raises in the period covered.
Sources (7)
- Integrated Annual Report FY2025-26
- Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
21Governance signals
21Governance signals
What do Dr. Reddy's' governance filings show?
- Auditor
- Deloitte Haskins & Sells LLP, since 2026
- Auditor changes
- 23 Jul 2026: S.R. Batliboi & Associates LLP → Deloitte Haskins & Sells LLP (Mandatory rotation, the company said. Shareholders appointed Deloitte at the 42nd AGM for five years, to the 47th AGM. S.R. Batliboi audited FY22–FY26.)
- Audit qualifications
- None reported
- Related-party dealings
- In FY26 Dr. Reddy's gave ₹74.4 crore of CSR money to Dr. Reddy's Foundation and paid Green Park Hospitality ₹49.0 crore for catering. It paid Indus Projects ₹26.2 crore for civil works and K Satish Reddy ₹1.9 crore in rent. Pay to key managers totalled ₹147.9 crore.
- Credit rating
- ICRA [ICRA]AA+ (long-term bank limits, ₹2,000 crore) (outlook Stable), 9 Jan 2026
A credit rating describes the company's ability to repay debt. It is not a rating of the share.
Flags to know about
regulatory · 14 Oct 2026
US FDA inspections awaiting classification
A Form 483 lists issues FDA inspectors observed. As of 11 Nov 2026, four inspections with Form 483s and one records assessment (Form FDA 2953) had no disclosed final classification: biologics, Bachupally (7 observations, Jun 2026); FTO-3, Bachupally (4, Aug 2026); API, Mexico (Form FDA 2953, 2, Sep 2026); FTO-11 (2) and FTO-9 (3), Oct 2026.
regulatory · 28 Oct 2026
Recent FDA inspections closed
The company disclosed VAI (voluntary action indicated) results for API Mirfield, UK (14 Aug 2026) and FTO-SEZ Process Unit-02, Srikakulam (28 Oct 2026). ICRA noted no warning letters, import alerts or OAI classifications in recent inspections (Jan 2026).
regulatory · 5 Mar 2026
US FCPA inquiries closed
After an anonymous complaint in Sep 2020 about Ukraine and other markets, the US SEC said on 23 Feb 2026 it does not intend to recommend enforcement action. The US Department of Justice closed its inquiry on 5 Mar 2026, the company disclosed.
other · 30 Jun 2026
US antitrust lawsuits pending
Dr. Reddy's is a defendant in US class actions alleging price-fixing of generic medicines, and in Revlimid (lenalidomide) antitrust suits, where motions to dismiss were pending. The company says most amounts cannot be reasonably estimated and has made no provision.
regulatory · 3 Oct 2026
Small tax penalties abroad
A Russian subsidiary's tax penalty of RUB 9.27 million (₹1.14 crore) became final on 13 Apr 2026; the company said it has no material impact. The IRS levied a USD 32,350 penalty on the US subsidiary in Oct 2026.
disclosure · 12 May 2026
Two sets of accounts
The company files Ind AS results in India and IFRS results for its US listing. FY26 profit for shareholders was ₹4,196 crore under Ind AS and ₹4,285 crore under IFRS. This page uses Ind AS.
other · 17 Sep 2025
Promoter shares moved to family trusts
On 17 Sep 2025 K Satish Reddy moved 9.06% to the VSD Family Trust and G V Prasad 11.51% to the GVP Family Trust. The promoter group's total holding did not change.
Sources (19)
- AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments
- Press release: intention to appoint Deloitte Haskins & Sells LLP as statutory auditors from FY2026-27
- Integrated Annual Report FY2025-26
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations
- Intimation: US FDA GMP inspection at formulations facility FTO-3, Bachupally: Form 483 with 4 observations
- Intimation: US FDA records assessment at API facility, Mexico: Form FDA 2953 with 2 observations
- Intimation: US FDA PAI at FTO-11, Pydibhimavaram: Form 483 with 2 observations
- Intimation: US FDA PAI at FTO-9, Visakhapatnam: Form 483 with 3 observations
- Intimation: US FDA classifies API Mirfield (UK) inspection as VAI
- Intimation: US FDA classifies FTO-SEZ Process Unit-02 inspection as VAI
- Disclosure: US SEC concludes FCPA investigation, no enforcement recommended
- Disclosure: US DOJ closes FCPA inquiry
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Intimation: final tax penalty decision for Russian subsidiary
- Intimation: IRS penalty on US subsidiary Dr. Reddy's Laboratories, Inc.
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
- Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust
- Shareholding pattern as of Sep 2026 (NSE XBRL)
22What the market paid
22What the market paid · price as of 11 Nov 2026
What did the market pay for Dr. Reddy's on 11 Nov 2026?
Price as of 11 Nov 2026 (shown for education; prices change daily).
Price as of 11 Nov 2026: ₹1,377.00, the NSE closing price. Market value = price × 834,680,285 shares (Sep 2026 shareholding filing) = ₹114,935 crore. P/E (market value per rupee of yearly profit) = market value ÷ profit of the last four quarters (Q3 FY26 to Q2 FY27, ₹2,799.9 crore) = 41.0; those quarters include the Q4 FY26 and Q1 FY27 one-off charges. On FY26 diluted earnings per share of ₹50.35 the P/E is 27.3. P/B = market value ÷ shareholders' equity on 30 Sep 2026 (₹38,807 crore) = 3.0. Dividend yield = FY26 dividend of ₹8 ÷ price = 0.58%. All are Cityfort calculations from the NSE bhavcopy and the company's filings.
- Share price
- ₹1,377.00
- Market value (market cap)
- ₹114,935 cr
- P/E
- 41×
- P/B
- 3×
Source: NSE capital market bhavcopy, 11 Nov 2026 (DRREDDY EQ close); Shareholding pattern as of Sep 2026 (NSE XBRL); Q3 FY26 consolidated financial results (Ind AS, NSE XBRL) and 4 more
Sources (7)
- NSE capital market bhavcopy, 11 Nov 2026 (DRREDDY EQ close)
- Shareholding pattern as of Sep 2026 (NSE XBRL)
- Q3 FY26 consolidated financial results (Ind AS, NSE XBRL)
- Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL)
- Q1 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q2 FY27 consolidated financial results (Ind AS, NSE XBRL)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
23How it got here
23How it got here
How did Dr. Reddy's get here?
1984
Milestone
Incorporated
Dr. Reddy's was incorporated in 1984 and made its first public share issue on 9 Aug 1986, according to its FY26 annual report. Its registered office is in Hyderabad.
2001
Milestone
Listed in New York
Its ADRs began trading on the New York Stock Exchange on 11 Apr 2001. Cheminor Drugs merged into the company in Jan 2001.
2022
Milestone
Promoter holding company merged in
The NCLT approved the merger of Dr. Reddy's Holdings, the promoters' holding company, into Dr. Reddy's on 5 Apr 2022. The promoters indemnify the company for a tax reassessment of that merger.
2024
Business-model change
Bought nicotine replacement brands
It bought Haleon's nicotine replacement portfolio, including Nicotinell, consolidated from Q3 FY25. Europe revenue rose 55% in FY26 (company figure).
2024
Milestone
Shares split 1:5
Each ₹5 share became five ₹1 shares from 28 Oct 2024.
2025
Milestone
Promoter shares moved to family trusts
On 17 Sep 2025 the two promoters moved 20.58% of the company to two family trusts; the promoter total did not change.
2026
Crisis
US lenalidomide exclusivity ended
Exclusivity ended in Jan 2026. Q4 FY26 revenue carried a ₹453 crore shelf-stock adjustment, and North America revenue fell 22% in FY26 (company figure).
2026
Crisis
Semaglutide launched, then paused
Launched in India on 21 Mar 2026 and Canada on 15 May 2026. On 9 Jul 2026 batches failed specification, and supplies were delayed.
2026
Milestone
New auditor
Deloitte Haskins & Sells LLP replaced S.R. Batliboi & Associates as statutory auditor at the 23 Jul 2026 AGM, a mandatory rotation.
Sources (10)
- Integrated Annual Report FY2025-26
- Business Responsibility and Sustainability Report FY2025-26
- ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable)
- Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF)
- Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust
- Press release: launch of semaglutide injection (Obeda) in India
- Press release: launch of generic semaglutide injection in Canada
- Intimation: semaglutide batches out of specification due to API issue; supplies delayed
- AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments
- Press release: intention to appoint Deloitte Haskins & Sells LLP as statutory auditors from FY2026-27
24Sources and changes
Where every number on this page comes from
Sources (60 documents)
- S1Integrated Annual Report FY2025-26 · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Jun 2026
- S2Business Responsibility and Sustainability Report FY2025-26 · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 30 Jun 2026
- S3Q2 FY27 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 23 Oct 2026
- S4Q2 FY27 results filing: board outcome and financial results (PDF) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Oct 2026
- S5Q2 FY27 results presentation (IFRS) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Oct 2026
- S6Q2 FY27 earnings call transcript (23 Oct 2026) · Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 29 Oct 2026) · Tier 1: company or exchange filing · 29 Oct 2026
- S7Q1 FY27 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 22 Jul 2026
- S8Q1 FY27 results filing (PDF, notes) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 22 Jul 2026
- S10Q1 FY27 earnings call transcript (22 Jul 2026) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 28 Jul 2026
- S11Q4 FY26 and FY26 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 12 May 2026
- S12Q4 FY26 results filing: press release (IFRS) and Ind AS results with notes (PDF) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 12 May 2026
- S13Q4 FY26 earnings call transcript (12 May 2026) · Dr. Reddy's Laboratories Ltd (company website; filed with NSE/BSE 18 May 2026) · Tier 1: company or exchange filing · 18 May 2026
- S14Q3 FY26 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jan 2026
- S17Q2 FY26 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 24 Oct 2025
- S18Q1 FY26 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 23 Jul 2025
- S19Q4 FY25 and FY25 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 9 May 2025
- S20Q4 FY25 results filing (PDF; FY24 comparatives and split-adjusted EPS) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 9 May 2025
- S21Q3 FY25 consolidated financial results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 24 Jan 2025
- S22Q4 FY24 and FY24 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 7 May 2024
- S23Q4 FY24 results filing (PDF; FY23 comparatives) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 7 May 2024
- S24Q4 FY23 and FY23 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 10 May 2023
- S25Q4 FY22 and FY22 audited consolidated results (Ind AS, NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 May 2022
- S26Shareholding pattern as of Dec 2023 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Jan 2024
- S27Shareholding pattern as of Mar 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Apr 2024
- S28Shareholding pattern as of Jun 2024 (revised filing) (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Jul 2024
- S29Shareholding pattern as of Sep 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2024
- S30Shareholding pattern as of Dec 2024 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jan 2025
- S31Shareholding pattern as of Mar 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 19 Apr 2025
- S32Shareholding pattern as of Jun 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2025
- S33Shareholding pattern as of Sep 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 16 Oct 2025
- S34Shareholding pattern as of Dec 2025 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 20 Jan 2026
- S35Shareholding pattern as of Mar 2026 (revised filing) (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2026
- S36Shareholding pattern as of Jun 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Jul 2026
- S37Shareholding pattern as of Sep 2026 (NSE XBRL) · NSE (company filing) · Tier 1: company or exchange filing · 21 Oct 2026
- S38ICRA rating rationale: Dr. Reddy's Laboratories Ltd, rating reaffirmed [ICRA]AA+ (Stable) · ICRA Ltd · Tier 2: rating agency or regulator · 9 Jan 2026
- S40NSE capital market bhavcopy, 11 Nov 2026 (DRREDDY EQ close) · National Stock Exchange of India · Tier 1: company or exchange filing · 11 Nov 2026
- S41Intimation: semaglutide batches out of specification due to API issue; supplies delayed · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 9 Jul 2026
- S42Disclosure: promoters transfer 20.58% to VSD Family Trust and GVP Family Trust · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 18 Sep 2025
- S43Disclosure: US SEC concludes FCPA investigation, no enforcement recommended · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 24 Feb 2026
- S44Disclosure: US DOJ closes FCPA inquiry · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 6 Mar 2026
- S45Press release: intention to appoint Deloitte Haskins & Sells LLP as statutory auditors from FY2026-27 · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Jul 2025
- S46AGM 23 Jul 2026 outcome: Deloitte Haskins & Sells LLP appointed statutory auditors; director appointments · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Jul 2026
- S48Intimation: US FDA pre-license inspection at biologics facility, Bachupally: Form 483 with 7 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 25 Jun 2026
- S49Intimation: US FDA classifies API Mirfield (UK) inspection as VAI · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Aug 2026
- S51Intimation: US FDA classifies FTO-SEZ Process Unit-02 inspection as VAI · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 28 Oct 2026
- S52Intimation: US FDA GMP inspection at formulations facility FTO-3, Bachupally: Form 483 with 4 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Aug 2026
- S53Intimation: US FDA records assessment at API facility, Mexico: Form FDA 2953 with 2 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 11 Sep 2026
- S54Intimation: US FDA PAI at FTO-11, Pydibhimavaram: Form 483 with 2 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 8 Oct 2026
- S55Intimation: resignation of Deepak Sapra, CEO API and Services · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 13 Aug 2026
- S56Intimation: appointment of Akhil Ravi as Head API and Services · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 23 Oct 2026
- S57Intimation: US FDA PAI at FTO-9, Visakhapatnam: Form 483 with 3 observations · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Oct 2026
- S59Intimation: final tax penalty decision for Russian subsidiary · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 14 Apr 2026
- S60Intimation: IRS penalty on US subsidiary Dr. Reddy's Laboratories, Inc. · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 3 Oct 2026
- S62Disclosure: Immutep update on TACTI-004 Phase III (eftilagimod alfa) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 13 Mar 2026
- S64Press release: launch of semaglutide injection (Obeda) in India · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 21 Mar 2026
- S67Press release: launch of generic semaglutide injection in Canada · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 16 May 2026
- S69Disclosure: exclusive distribution agreement with Takeda for Qdenga (India private market) · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 18 Sep 2026
- S70Press release: marketing authorization for generic semaglutide injection in Brazil · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 5 Nov 2026
- S71AGM 24 Jul 2025 outcome: re-appointment of G V Prasad as Co-Chairman and MD · Dr. Reddy's Laboratories Ltd (filing to NSE/BSE) · Tier 1: company or exchange filing · 24 Jul 2025
- S72Sun Pharmaceutical Industries: investor presentation, September 2026 ("Creating Lasting Value"), India market share chart (AIOCD AWACS, MAT Jun 2026) · Sun Pharmaceutical Industries Ltd (company IR site; same document filed with NSE/BSE) · Tier 1: company or exchange filing · 22 Sep 2026
Changes to this page (v2 · 17 Nov 2026)
- v2 · 17 Nov 2026Reworded the margin caption so it names the company (no numbers changed). (editorial update, Q2 FY27)
- v1 · 11 Nov 2026First version. (first version)
Numbers come only from tier 1 and tier 2 sources. Read how we research.
Disclaimer
For learning only. Cityfort is not a SEBI-registered adviser and does not recommend buying or selling any security. Prices shown are dated and may be out of date.
Investing in securities involves risk, including loss of capital. Before making any investment decision, do your own research and consider consulting a SEBI-registered investment adviser.
Cityfort, its owners and contributors may or may not hold securities of companies covered. Content is not an offer or solicitation to buy or sell any security.
Read the full disclaimerHide the full disclaimer
Cityfort publishes educational content that explains how listed companies work. Cityfort is not registered with the Securities and Exchange Board of India (SEBI) as an Investment Adviser or Research Analyst and does not provide investment advice, recommendations, ratings, price targets or any opinion on whether to buy, sell or hold any security.
All information is taken from publicly available sources, mainly company filings on BSE and NSE, which are listed on each page with dates. We work to keep it accurate and correct errors publicly, but we do not guarantee that it is complete, accurate or up to date. Any market price or price-based ratio shown is dated, may be out of date by the time you read it, and is included only to explain concepts.
Statements by company management are reported as statements, with their date and source; they are not our forecasts.